Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CPO 301

Next Previous
Drug Profile

CPO 301

Alternative Names: CPO-301; SYS-6010

Latest Information Update: 04 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Conjupro Biotherapeutics
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Clinical Phase Unknown Colorectal cancer; Gastrointestinal cancer

Most Recent Events

  • 01 Dec 2025 CSPC Megalith Biopharmaceutical plans a phase II trial for Non-small Cell Lung Cancer (Neoadjuvant therapy, Combination therapy) (IV, Infusion) (NCT07256509)
  • 28 Nov 2025 CSPC Megalith Biopharmaceutical plans a phase II trial for Head and neck squamous cell carcinoma (Combination therapy, Recurrent , Metastatic disease) in undisclosed location (Parenteral, injection) in December 2025 (NCT07254585)
  • 26 Nov 2025 CSPC Megalith Biopharmaceutical plans a phase II/III trial for Esophageal squamous cell carcinoma (Combination therapy, Late-stage disease, Metastatic disease, First-line therapy) in December 2025 (IV) (NCT07251062)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top